Skip to main navigation
Skip to main content
Skip to Footer
English
Français
Canada
Répertoire du site Sandoz
Our Work
What We Do
Quality Generics
Biopharmaceuticals
Specialty Products
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Contact Us
Grants, Donations and Sponsorships
Products
Consumers
Patients
Healthcare Professionals
Patient Support Programs
News
Media Releases
Media Resource Center
Stay Up-To-Date
Careers
Available Positions
Diversity & Inclusion
Our Benefits
Sandoz-Connect Portal
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Filter By
2023
May
Story
/
May 17, 2023
Sandoz Canada improves patients’ access to treatment with the launch of three new generics
Read More
Media Release
/
May 17, 2023
Sandoz Canada improves patients’ access to treatment with the launch of three new generics
Read More
March
Media Release
/
Mar 24, 2023
Shortage of Nitroglycerin Spray 0.4 mg
Read More
Media Release
/
Mar 09, 2023
Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines
Read More
January
Media Release
/
Jan 10, 2023
Sandoz Canada Launches PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin
Read More
Story
/
Jan 10, 2023
Sandoz Canada Launches PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin
Read More
2022
December
Media Release
/
Dec 21, 2022
Sandoz Canada supports Ontario policy change to cover biosimilars which will generate significant cost savings and improve patient access to quality medicines
Read More
November
Media Release
/
Nov 14, 2022
Sandoz Canada launches PrSandoz® Apremilast
Read More
October
Media Release
/
Oct 25, 2022
Novartis Q3 2022 financial results
Read More
September
Media Release
/
Sep 21, 2022
Sandoz Canada continues to expand its portfolio of generic products
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
You are here
Home
›
